Feline
Update (June 11, 2026): Long-Term Oclacitinib Well Tolerated for Feline Allergic Pruritus in a 14-Cat Retrospective
TL;DR
A 2025 retrospective study of 14 cats found long-term oclacitinib for allergic pruritus was well tolerated over a median of about 15 months, with only mild and frequently transient laboratory changes, and the daily dose could be reduced by at least half in half the cats.
What just dropped
Urkiola, Bardagi and colleagues published "Long-term oclacitinib administration for the control of feline allergic pruritus: A retrospective study of 14 client-owned cats" in The Canadian Veterinary Journal (August 2025;66(8):835-842). Oclacitinib is licensed for dogs, and feline data remain limited, so this clinical-and-laboratory series addresses a real off-label question for the cat in front of you.
- Fourteen client-owned cats with pruritic allergic dermatitis controlled on oclacitinib were studied retrospectively, with clinical data and blood testing evaluated at onset and at least once during treatment.
- The median duration of treatment was 15.5 months; in 7 of the 14 cats the maintenance dose could be reduced by at least 50 percent, usually after about 15 days of treatment (dose figures: see the source and the current label).
- Laboratory changes during treatment were mild and frequently transient, including hypercholesterolaemia, increased alanine aminotransferase and/or creatinine, and hyperglycaemia; limited, transitory disruptions in platelet and white-cell-lineage numbers were seen in some cats but none required specific treatment or discontinuation.
- Four cats developed non-dermatologic disorders that resolved without changing the oclacitinib schedule; the authors concluded long-term oclacitinib appeared well tolerated and effective but recommended close monitoring and larger prospective studies.
Context
Feline atopic skin syndrome and allergic pruritus are common but have fewer licensed pharmacological options than the canine equivalent, and clinicians often reach for drugs approved in dogs. The relevant safety reassurance comes from a separate blinded, randomized, placebo-controlled trial in healthy cats (BMC Veterinary Research 2019), in which oral oclacitinib maleate was well tolerated over 28 days, with no clinical signs of toxicity at the lower dose tested, only mild gastrointestinal signs at the higher dose, haematologic shifts that stayed within reference ranges, and normal renal and liver enzymes throughout.
Read together, the controlled short-term safety trial and the longer real-world retrospective give a consistent picture: oclacitinib is generally well tolerated in cats, with laboratory changes that are usually mild and reversible, though the evidence base remains small and standardised feline dosing has not been established.
What this changes in the Oclacitinib (Apoquel) evergreen
The oclacitinib atopic-dermatitis page (https://www.thevoyage.ai/forvets/knowledge/oclacitinib-canine-atopic-dermatitis) is focused on the licensed canine indication and JAK1 mechanism. This update flags the growing, if still limited, feline evidence: a 15.5-month median retrospective in 14 cats showing good tolerability and the feasibility of dose reduction in half the cohort, backed by a controlled 28-day safety trial in healthy cats. The practical message is that off-label oclacitinib use in pruritic cats is supported by small but consistent safety data, warrants close clinical and laboratory monitoring, and still lacks the standardised dosing and large prospective trials that would let it be recommended with confidence. Any dosing decision should follow the current product label and clinical judgement.
References
- Urkiola A, Cervantes S, Carrasco I, Dalmau A, Bardagi M. Long-term oclacitinib administration for the control of feline allergic pruritus: A retrospective study of 14 client-owned cats. The Canadian Veterinary Journal. 2025;66(8):835-842. https://www.ingentaconnect.com/contentone/cvma/cvj/2025/00000066/00000008/art00005
- A blinded, randomized, placebo-controlled trial of the safety of oclacitinib in cats. BMC Veterinary Research. 2019;15:283. https://link.springer.com/article/10.1186/s12917-019-1893-x
Voyage Clinical Desk
From clinical question to SOAP draft - cited differentials, live dose calculators, owner handouts. Trained on the veterinary canon (Plumb's, Ettinger, JVIM, ACVIM consensus, 50,000+ indexed references). First answer free, no signup.
Open Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=update-2026-06-11-oclacitinib-feline-allergic-pruritus
Changelog
- 2026-06-11: First published.
Related reads
References
More clinical updates
Enflicoxib (Daxocox) for Canine Osteoarthritis: A Once-Weekly COX-2 Selective NSAID
Enflicoxib (Daxocox) is an EU-authorised, once-weekly COX-2 selective NSAID for canine osteoarthritis. Mechanism, long-term 6-month field efficacy and safety, and clinical placement reviewed.
Read →Update (June 11, 2026): Bedinvetmab Improves Activity and Body Composition in Obese Dogs with Osteoarthritis
An April 2026 randomized placebo-controlled trial found bedinvetmab improved objective activity and pain and preserved thigh muscle in obese dogs with osteoarthritis, with no adverse effects reported.
Read →Update (June 11, 2026): RCVS Knowledge Appraisal Rates Grapiprant Osteoarthritis Evidence as Weak
A 2026 RCVS Knowledge critically appraised topic rated the evidence that grapiprant reduces canine osteoarthritic pain as weak: benefit on chronic OA outcomes but no improvement in acute, severe lameness.
Read →Update (June 11, 2026): Pooled Analysis Finds Robenacoxib Safety Comparable to Placebo in Cats with CKD
A pooled analysis of four RCTs found robenacoxib did not significantly raise adverse-event risk versus placebo in cats with chronic musculoskeletal disease, including a 126-cat chronic-kidney-disease subgroup.
Read →